EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ATP13A3 variants promote pulmonary arterial hypertension by disrupting polyamine transport

Bin Liu, Mujahid Azfar, Ekaterina Legchenko, James A West, Shaun Martin, Chris Van den Haute, Veerle Baekelandt, John Wharton, Luke Howard, Martin R Wilkins, Peter Vangheluwe, Nicholas W Morrell und 1 weitere

Cardiovascular Research · 2024

DOI: 10.1093/cvr/cvae068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2024. Verfasst von Bin Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardio and Respiratory Medicine, Department of Medicine, Victor Phillip Dahdaleh Heart and Lung Research Institute, Papworth Road, Cambrid…. Hauptthemen laut MEDLINE: Endothelial Cells, Polyamines, Membrane Transport Proteins, Adenosine Triphosphatases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council, Cambridge Trust International Scholarship, Great Britain-China Educational Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Potential loss-of-function variants of ATP13A3, the gene encoding a P5B-type transport ATPase of undefined function, were recently identified in patients with pulmonary arterial hypertension (PAH). ATP13A3 is implicated in polyamine transport but its function has not been fully elucidated. In this study, we sought to determine the biological function of ATP13A3 in vascular endothelial cells (ECs) and how PAH-associated variants may contribute to disease pathogenesis. Methods and results We studied the impact of ATP13A3 deficiency and overexpression in EC models [human pulmonary ECs, blood outgrowth ECs (BOECs), and human microvascular EC 1], including a PAH patient–derived BOEC line harbouring an ATP13A3 variant (LK726X). We also generated mice harbouring an Atp13a3 variant analogous to a human disease–associated variant to establish whether these mice develop PAH. ATP13A3 localized to the recycling endosomes of human ECs. Knockdown of ATP13A3 in ECs generally reduced the basal polyamine content and altered the expression of enzymes involved in polyamine metabolism. Conversely, overexpression of wild-type ATP13A3 increased polyamine uptake. Functionally, loss of ATP13A3 was associated with reduced EC proliferation, increased apoptosis in serum starvation, and increased monolayer permeability to thrombin. The assessment of five PAH-associated missense ATP13A3 variants (L675V, M850I, V855M, R858H, and L956P) confirmed loss-of-function phenotypes represented by impaired polyamine transport and dysregulated EC function. Furthermore, mice carrying a heterozygous germline Atp13a3 frameshift variant representing a human variant spontaneously developed a PAH phenotype, with increased pulmonary pressures, right ventricular remodelling, and muscularization of pulmonary vessels.

Conclusion

We identify ATP13A3 as a polyamine transporter controlling polyamine homeostasis in ECs, a deficiency of which leads to EC dysfunction and predisposes to PAH. This suggests a need for targeted therapies to alleviate the imbalances in polyamine homeostasis and EC dysfunction in PAH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endothelial CellsPolyaminesMembrane Transport ProteinsAdenosine TriphosphatasesAnimalsHumansMiceApoptosisBiological TransportCell ProliferationCells, CulturedDisease Models, AnimalEndosomesHypertension, PulmonaryMice, Inbred C57BLPhenotypeProton-Translocating ATPasesPulmonary Arterial HypertensionPulmonary Artery

Stichwörter der Autor:innen

ATP13A3PolyaminesPulmonary arterial hypertension

Substanzen

PolyaminesProton-Translocating ATPasesATP13A3 protein, humanMembrane Transport ProteinsAdenosine Triphosphatases

Autor:innen und Institutionen

  • Section of Cardio and Respiratory Medicine, Department of Medicine, Victor Phillip Dahdaleh Heart and Lung Research Institute, Papworth Road, Cambridge CB2 0BB, UK.
  • Department of Cellular and Molecular Medicine, KU Leuven, Herestraat 49, Box 802, 3000 Leuven, Belgium.
  • Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge CB2 0AW, UK.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Hills Road, Cambridge CB2 0QQ, UK.
  • Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK.
  • Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, KU Leuven, Herestraat 49, Box 1023, 3000 Leuven, Belgium.

ORCID-Profile: Paul D Upton

Förderung

  • China Scholarship Council
  • Cambridge Trust International Scholarship
  • Great Britain-China Educational Trust
  • Henry Lester Trust and Leche Trust
  • Fonds voor Wetenschappelijk Onderzoek
  • Flanders
  • Marie Sklodowska-Curie Postdoctoral Research
  • BHF Programme

Zitieren

APA

Liu, B., Azfar, M., Legchenko, E., West, J. A., Martin, S., Van den Haute, C., Baekelandt, V., Wharton, J., Howard, L., Wilkins, M. R., Vangheluwe, P., Morrell, N. W., & Upton, P. D. (2024). ATP13A3 variants promote pulmonary arterial hypertension by disrupting polyamine transport. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae068

Vancouver

Liu B, Azfar M, Legchenko E, West JA, Martin S, Van den Haute C, et al. ATP13A3 variants promote pulmonary arterial hypertension by disrupting polyamine transport. Cardiovascular Research. 2024. doi:10.1093/cvr/cvae068

BibTeX
@article{Liu2024,
  author = {Liu, Bin and Azfar, Mujahid and Legchenko, Ekaterina and West, James A and Martin, Shaun and Van den Haute, Chris and Baekelandt, Veerle and Wharton, John and Howard, Luke and Wilkins, Martin R and Vangheluwe, Peter and Morrell, Nicholas W and Upton, Paul D},
  title = {ATP13A3 variants promote pulmonary arterial hypertension by disrupting polyamine transport},
  journal = {Cardiovascular Research},
  year = {2024},
  doi = {10.1093/cvr/cvae068}
}
Kostenlos starten →